Zobrazeno 1 - 10
of 18
pro vyhledávání: '"T T, Soncrant"'
Autor:
Arnold Brossi, Debomoy K. Lahiri, H W Holloway, Nigel H. Greig, T. T. Soncrant, Donald K. Ingram, Joseph Deutsch, E De Micheli, Tracy Ann Perry, Q S Yu, T Utsuki
Publikováno v:
Acta Neurologica Scandinavica. 102:74-84
Phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (AChE) inhibitor, with a > 50-fold activity versus butyrylcholinesterase (BChE), in clinical trials for the treatment of Alzheimer's disease (AD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1d616ef21f262adedc6e9149db06ab2
https://doi.org/10.1034/j.1600-0404.2000.00311.x
https://doi.org/10.1034/j.1600-0404.2000.00311.x
Publikováno v:
Medicinal Research Reviews. 15:3-31
I . Historical Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. Target of Physostigmine an oids: Cholinesterase Enzymes . . . . . . . . A. Localization and Function . . . . . . . . . . . . . . .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4342eb2c9ea8565e4a1aa9e3bf6faa39
https://doi.org/10.1002/med.2610150103
https://doi.org/10.1002/med.2610150103
Publikováno v:
ChemInform. 26
I . Historical Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. Target of Physostigmine an oids: Cholinesterase Enzymes . . . . . . . . A. Localization and Function . . . . . . . . . . . . . . .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f133fe78f9c9ae67b04aaec9cc7a8323
https://doi.org/10.1002/chin.199525307
https://doi.org/10.1002/chin.199525307
Autor:
N H, Greig, E, De Micheli, H W, Holloway, Q S, Yu, T, Utsuki, T A, Perry, A, Brossi, D K, Ingram, J, Deutsch, D K, Lahiri, T T, Soncrant
Publikováno v:
Acta neurologica Scandinavica. Supplementum. 176
Phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (AChE) inhibitor, with a50-fold activity versus butyrylcholinesterase (BChE), in clinical trials for the treatment of Alzheimer's disease (AD).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7cba5b2a5cbf6ffc7b7fad557f88d7d9
https://pubmed.ncbi.nlm.nih.gov/11261809
https://pubmed.ncbi.nlm.nih.gov/11261809
Publikováno v:
Alzheimer disease and associated disorders. 9(4)
Physostigmine, a reversible and nonselective cholinesterase inhibitor, administered by steady-state, continuous intravenous infusion to carefully selected subjects with mild-moderate Alzheimer disease, produced significant but modest improvement in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4423494fe311fc13b7f6f7e92a5d704c
https://pubmed.ncbi.nlm.nih.gov/8749612
https://pubmed.ncbi.nlm.nih.gov/8749612
Publikováno v:
Psychopharmacology bulletin. 27(3)
Alzheimer's disease (AD) is accompanied by depletion of cholinergic markers in the central nervous system. In an attempt to improve cognitive function in AD, arecoline (a muscarinic cholinergic receptor agonist) was given to patients with probable or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a1f6285fb43c5a8d5fdcf027dbb2095d
https://pubmed.ncbi.nlm.nih.gov/1775605
https://pubmed.ncbi.nlm.nih.gov/1775605
Autor:
T T, Soncrant
Publikováno v:
International journal of clinical pharmacology research. 10(1-2)
Although brain aging is accompanied by measurable deficits in cognitive and motor function, and frequently by selective loss of neurons, neurotransmitters and their receptors, resting brain energy metabolism, purported to reflect neural function, und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6b2b86d8453cf220ab005ee0162c6639
https://pubmed.ncbi.nlm.nih.gov/1974889
https://pubmed.ncbi.nlm.nih.gov/1974889
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 249(1)
A number of carbamoyl- and N(1)-substituted analogs of physostigmine were synthesized and their in vitro potencies (IC50 values) vs. human erythrocyte and brain (cerebral cortex and caudate nucleus) acetylcholinesterase (AChE) and electric eel AChE a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5a09c0b94895aaa15586e33d534e3f2
https://pubmed.ncbi.nlm.nih.gov/2709330
https://pubmed.ncbi.nlm.nih.gov/2709330
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 245(2)
The pharmacokinetic distribution of human lymphoblastoid interferon (IFN-alpha), (Wellferon, Burroughs Wellcome Company, Research Triangle Park, NC) in plasma and seven tissues was studied for up to 4 hr after intravascular administration as a bolus,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::46f19d3bfece53dc98d99ef14bce65f0
https://pubmed.ncbi.nlm.nih.gov/2835475
https://pubmed.ncbi.nlm.nih.gov/2835475
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 245(2)
Pharmacokinetic parameters of human lymphoblastoid interferon (IFN-alpha) delivery to normal rat brain were examined. IFN-alpha concentrations in brain parenchyma could only be detected 120 min after its intravascular administration, and were 0.003%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::73cb61411d1c43aa6e30eafe15f9d814
https://pubmed.ncbi.nlm.nih.gov/3367308
https://pubmed.ncbi.nlm.nih.gov/3367308